Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package, achieving annual sales of approximately $69.9 million.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has received U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray. The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the Exchange about a copy of a newspaper publication regarding the 48th Annual General Meeting to be held on September 11, 2026, through Video Conferencing or Other Audio-Visual Means.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited sent letters to shareholders whose email addresses are not registered, providing a web link to access the Integrated Annual Report and Annual General Meeting Notice for FY 2025-26.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has entered into a settlement agreement with Humana for $15.28 million to resolve antitrust and consumer protection lawsuits in the US. The company denies any wrongdoing and the settlement does not constitute an admission of liability.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has allotted 23,863 equity shares under the Employee Stock Option Plan 2016 to the grantee who had exercised the options. The paid-up capital of the company has increased from Rs. 28,22,00,809 to Rs. 28,22,24,672.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the Exchange about the schedule of analyst/institutional investor meetings to be conducted in August and September 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication regarding the 48th Annual General Meeting to be held through Video Conferencing/OAVM on September 11, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the transcript of the Earnings Call held on August 3, 2026, for the quarter ended June 30, 2026, which has been uploaded on the Company's website.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has uploaded the audio recording of its Q1 FY 2026-27 earnings call on its website.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in accordance with SEBI regulations.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investor Presentation' for Q1 FY 27, with consolidated revenue of Rs. 40,185 million, a 23.1% YoY growth, and EBITDA of Rs. 8,048 million with a margin of 20.03%. The company has reported strong growth across its key markets, with India business growth of 15.5%, North America core business growth of 19.8%, and Emerging Markets business growth of 27.7%. The results reinforce the direction of Glenmark's next phase: strengthening its core businesses while expanding its differentiated specialty and innovation-led platforms.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced its Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million, driven by strong execution and resilience of its business. The company reported EBITDA of Rs. 8,048 million, a 38.6% YoY growth, and PAT of Rs. 4,828 million, with a PAT margin of 11.8%. The company's India formulations revenue grew 15.5% YoY, North America revenue grew 41.1% YoY, and Emerging Markets revenue grew 27.7% YoY.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - List of Officials'. The company has updated its officials authorized for determining materiality of events or information and making disclosures to the stock exchange.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹24,349.93 crore and profit after tax at ₹7,356.37 crore. The company has also announced a record date of August 31, 2026, for the purpose of determining the entitlement of dividend for the AGM to be held for the Financial Year ended March 31, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, and announced the 48th Annual General Meeting (AGM) to be held on September 11, 2026. The company also approved amendments to its policies, including the Policy on Related Party Transactions and its Materiality, and reconstituted its Risk Management Committee.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials in the US market, which is expected to generate significant revenue.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement for the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority, as per the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the schedule of an earnings call for the unaudited financial results for the quarter ended June 30, 2026. The call is scheduled to be held on August 03, 2026, from 8:30 am to 9:30 am IST.